Q2 FY26 Earnings January 29, 2026 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial ...

Financial Performance - Revenue for the second quarter of fiscal year 2026 increased by 11% year-over-year to $1.4 billion, with a 9% increase on a constant currency basis[5]. - Diluted earnings per share for the quarter was $2.68, representing a 15% increase compared to the prior year, while non-GAAP diluted earnings per share increased by 16% to $2.81[5][9]. - Net income for the quarter was $392.6 million, a 14% increase from the previous year[6][9]. - Total revenue for the three months ended December 31, 2025, was $1,422.8 million, an 11% increase compared to $1,282.1 million for the same period in 2024[24]. - For the six months ended December 31, 2025, total revenue was $2,758.4 million, a 10% increase from $2,506.6 million in 2024[24]. Margins and Profitability - Non-GAAP gross margin expanded by 310 basis points to 62.3%, driven by manufacturing efficiencies and component cost improvements[5][9]. - GAAP gross margin improved to 61.8% for the three months ended December 31, 2025, compared to 58.6% in 2024[20]. - Non-GAAP gross profit for the three months ended December 31, 2025, was $886,532, up from $758,909 in 2024, indicating a growth of 17%[20]. Cash Flow and Assets - Operating cash flow for the quarter was $340 million, reflecting strong financial performance[9]. - Cash and cash equivalents at the end of the period were $1,417,069, an increase from $1,209,450 at the beginning of the period, marking a rise of 17%[18]. - Net cash provided by operating activities for the six months ended December 31, 2025, was $797,066, compared to $634,161 in 2024, reflecting a year-over-year increase of 26%[18]. - Total assets increased to $8,503,370, up from $8,174,391, representing a growth of 4%[17]. Shareholder Returns and Capital Management - The company declared a quarterly cash dividend of $0.60 per share, payable on March 19, 2026[8]. - The company repurchased 704,000 shares for $175 million as part of its capital management strategy[9]. Expenses and Investments - Research and development expenses increased by 12% year-over-year, reflecting ongoing investment in innovation[6][9]. Market Performance - Revenue in the U.S., Canada, and Latin America grew by 11%, while revenue in Europe, Asia, and other markets increased by 6% on a constant currency basis[7]. - Total Sleep and Breathing Health revenue reached $1,255.9 million for the three months ended December 31, 2025, up 12% from $1,125.6 million in 2024[24]. - Combined revenue from Europe, Asia, and other markets for the three months ended December 31, 2025, was $420.9 million, a 12% increase from $376.6 million[24]. - Devices revenue in combined Europe, Asia, and other markets was $278.2 million, a 9% increase from $254.8 million[24]. - The company reported a 7% increase in Residential Care Software revenue for the three months ended December 31, 2025, totaling $166.9 million compared to $156.5 million in 2024[24]. - Constant currency measures indicate that the company’s revenue growth is consistent across different markets, excluding foreign currency fluctuations[25]. Debt and Liabilities - Total current liabilities rose to $1,248,114, up from $1,019,120, reflecting a 22% increase[17]. - Long-term debt decreased to $403,923 from $658,392, a reduction of 39%[17]. - Total stockholders' equity increased to $6,320,879, up from $5,967,859, indicating a growth of 6%[17].

Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Resmed I ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. ResMed (RMD) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.ResMed is one of 929 individual stocks in the Medical sector. Collectively, these companies sit at #10 i ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

The upcoming report from ResMed (RMD) is expected to reveal quarterly earnings of $2.68 per share, indicating an increase of 10.3% compared to the year-ago period. Analysts forecast revenues of $1.39 billion, representing an increase of 8.3% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company reve ...

Core Insights - Resmed (RMD) is scheduled to announce its second-quarter fiscal 2026 results on January 29, with adjusted earnings per share (EPS) of $2.55 in the last quarter, exceeding the Zacks Consensus Estimate by 2.41% [1] Group 1: Q2 Estimates - The Zacks Consensus Estimate for Resmed's revenues in Q2 fiscal 2026 is $1.39 billion, reflecting an 8.3% increase from the previous year [2] - The EPS estimate for the same quarter suggests a 10.3% rise to $2.68 [2] Group 2: Estimate Revision Trend - Earnings estimates for Resmed's fiscal second-quarter have remained stable over the past 60 days, indicating consistent expectations leading up to the announcement [3] Group 3: Factors Influencing Q2 Results - Strong demand for Resmed's mask portfolio in the U.S., Canada, and Latin America is expected to drive growth, with additional contributions from the VirtuOx acquisition [4] - Recent product innovations in the mask portfolio, such as the AirTouch F30i Comfort and AirTouch F30i Clear, are anticipated to positively impact revenues [5] - The integration of machine learning, AI, and generative AI in digital health products, including the Dawn personal sleep health assistant, may enhance overall revenue [6] - Device sales are likely to benefit from the availability of AirSense 10 and AirSense 11 sleep devices, with a projected 6.3% revenue increase in the Sleep and Breathing Health segment [7] Group 4: Residential Care Software - The Residential Care Software division is crucial for supporting the core Sleep and Breathing Health business, with expected revenue growth of 7.1% in Q2 fiscal 2026 [10] - The company is focusing on high-growth, higher-margin areas while reducing exposure to lower-growth segments [9] Group 5: Earnings ESP and Zacks Rank - Resmed has an Earnings ESP of -0.81%, indicating a lower chance of beating estimates, while holding a Zacks Rank of 2 (Buy) [11]

The market expects ResMed (RMD) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on January 29, might help the stock move higher if these key numbers are better t ...

Core Viewpoint - The U.S. stock market experienced a decline primarily due to Nvidia's ban on H200 AI chips in China, which negatively impacted major technology stocks and bank earnings [2][10]. Market Overview - The three major U.S. stock indices fell on January 14, 2026, with Nvidia's decline leading the way, affecting other technology stocks [2]. - Major banks like Citigroup and Wells Fargo reported disappointing fourth-quarter results, contributing to the market's downturn [2]. Investment Strategy - Investors are advised to favor low-leverage stocks over high-growth technology stocks to mitigate risks associated with high-debt companies [3][10]. - Recommended companies include REV Group (REVG), TechnipFMC (FTI), Resmed (RMD), Zurn Elkay Water Solutions (ZWS), and SEI Investments (SEIC), all of which exhibit low leverage and solid growth prospects [3][10]. Significance of Low-Leverage Stocks - Leverage refers to borrowing capital for operations and expansion, typically through debt financing, which can pose risks if not managed properly [5][6]. - Companies with excessive reliance on debt financing may face significant losses during economic downturns, making low-leverage stocks a safer investment choice [6][7]. Debt Analysis - The debt-to-equity ratio is a key metric for assessing a company's financial risk, with lower ratios indicating better solvency [8]. - Investors should focus on stocks with solid earnings growth and low debt-to-equity ratios, especially during earnings seasons [8][10]. Stock Recommendations - **REV Group (REVG)**: Reported a 11.1% year-over-year increase in net sales to $664.4 million and a 62.7% surge in adjusted earnings per share [14][15]. - **TechnipFMC (FTI)**: Awarded a significant contract by BP, with a projected revenue increase of 6.6% for 2026 [16][17]. - **Resmed (RMD)**: Received FDA clearance for an AI-enabled medical device, with an expected 8.4% revenue growth for 2026 [18][19]. - **Zurn Elkay Water Solutions (ZWS)**: Recognized as one of America's Most Responsible Companies, with a projected revenue increase of 5.3% for 2026 [20][21]. - **SEI Investments (SEIC)**: Completed multiple client projects, with a forecasted revenue growth of 9.3% for 2026 [22][23].

Company Overview - ResMed is a 36-year-old company that originated as a spinout from Baxter, with an initial technology investment of approximately AUD 1.2 million (around USD 800,000) [3] - The current market capitalization of ResMed is approximately $37 billion, indicating a significant return on investment [3] Financial Performance - For the trailing 12 months, ResMed reported revenues of $5.3 billion, showcasing strong financial performance [4] - The company has maintained robust gross margins and net operating profit margins exceeding 30%, with non-GAAP margins at 33% and GAAP margins at 35% [4]